iShares iBoxx $ High Yield Corporate Bond ETF vs Philip Morris International Inc. — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.65, while Philip Morris International Inc. trades at $188.62 (market cap $300.37B). The key difference: Philip Morris International Inc. pays a 3.05% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none, and Philip Morris International Inc. is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| HYG | PM | |
|---|---|---|
Sector | Fixed Income | Consumer Staples |
52-Week High | $81.32 | $192.98 |
52-Week Low | $78.72 | $144.33 |
Market Cap | — | $300.37B |
Enterprise Value | — | $346.86B |
Dividend Yield | — | 3.05% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Philip Morris International (PM) trades at $192.98, up 1.65% today, near the analyst consensus price target of $194. The stock shows a bullish technical trend with strong moving average support. Fundamentally, the company reported robust 2025 results with revenue of $40.65 billion and net income of $11.35 billion, though recent news highlights a $500 million impairment charge and reduced profit guidance for 2026 due to cost pressures.
The outlook remains cautiously optimistic with 68% of analysts rating it a Buy, but investors face headwinds from currency volatility, rising illicit tobacco trade in Europe, and margin compression. The stock's valuation at a P/E of 27.13 appears full priced, requiring continued execution to justify further upside.
Trailing returns across standard periods
Latest headlines on both assets
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →